Quark Pharmaceuticals to Present New Preclinical Proof of Concept Results at JPMorgan 26th Annual Healthcare Conference

Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans. Commences Phase I Clinical Trial of Proprietary siRNA Molecule in Acute Renal Failure.

Quark Pharmaceuticals to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

Quark Pharmaceuticals, Inc. to Receive Development Milestone Payment from Mitsubishi Pharma Corporation

Quark Pharmaceuticals Signs Collaboration Agreement with University of Michigan for Development of Proprietary siRNA Compounds for Noise-Induced Hearing Loss

 Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications To Its RNAi Molecules

Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss

Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Quark to initiate Phase 1 trial of AKIi-5 as the first human clinical study involving the systemic delivery of siRNA

Silence Therapeutics plc and Quark Pharmaceuticals, Inc. (“Quark”), announced today an expansion of their current strategic technology licensing agreement